HIGHLIGHTS
- who: Jia Zhu from the Spain Catholic University of the Sacred have published the Article: Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma, in the Journal: (JOURNAL) of March/31,/2019
- what: This study was approved by the Ethics Board of the Sun Yatsen University Cancer Center and conducted in accordance with the Helsinki Declaration. The overall objective response (complete response + partial response) in the cohort was 69.6% (34/46) with 7.3 months median progression free time which may have contributed to raise the opportunity for local control. The study has . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.